Skip to main content
Journal cover image
Intraocular Drug Delivery

Drug delivery for proliferative vitreoretinopathy: Prevention and treatment

Publication ,  Chapter
Phillips, SJ; Jaffe, GJ
January 1, 2006

Despite improvements in surgical technique, proliferative vitreoretinopathy (PVR) remains a common and significant vision-threatening complication of retinal detachment repair and trauma. A clinically significant form of PVR occurs following approximately 5–10% of all rhegmatogenous detachment repairs (1–6). In these eyes, PVR typically develops approximately six weeks after the initial surgical repair. In eyes with established severe PVR at the time of surgery, postoperative reproliferation and redetachment occurs in up to 55% of cases (7).

Duke Scholars

ISBN

9780824728601

Publication Date

January 1, 2006

Start / End Page

279 / 290
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Phillips, S. J., & Jaffe, G. J. (2006). Drug delivery for proliferative vitreoretinopathy: Prevention and treatment. In Intraocular Drug Delivery (pp. 279–290).
Phillips, S. J., and G. J. Jaffe. “Drug delivery for proliferative vitreoretinopathy: Prevention and treatment.” In Intraocular Drug Delivery, 279–90, 2006.
Phillips SJ, Jaffe GJ. Drug delivery for proliferative vitreoretinopathy: Prevention and treatment. In: Intraocular Drug Delivery. 2006. p. 279–90.
Phillips, S. J., and G. J. Jaffe. “Drug delivery for proliferative vitreoretinopathy: Prevention and treatment.” Intraocular Drug Delivery, 2006, pp. 279–90.
Phillips SJ, Jaffe GJ. Drug delivery for proliferative vitreoretinopathy: Prevention and treatment. Intraocular Drug Delivery. 2006. p. 279–290.
Journal cover image

ISBN

9780824728601

Publication Date

January 1, 2006

Start / End Page

279 / 290